Mestrado Profissional em Avaliação de Tecnologias em Saúde

URI Permanente desta comunidade

https://dspace.inc.saude.gov.br/handle/123456789/15

Navegar

Navegando Mestrado Profissional em Avaliação de Tecnologias em Saúde por Autor "Acosta, Angela"

Agora exibindo 1 - 1 de 1
  • Item
    Data sources for drug utilization research in Latin American countries—A cross-national study: DASDUR-LATAM study
    (Pharmacoepidemiology and Drug Safety, 2022) Lopes, Luciane C.; Salas, Maribel; Osorio-de-Castro, Claudia Garcia Serpa; Leal, Lisiane Freitas; Doubova, Svetlana V.; Cañás, Martín; Dreser, Anahi; Acosta, Angela; Baldoni, Andre Oliveira; Bergamaschi, Cristiane de Cássia; Mota, Daniel Marques; Gomez-Galicia, Diana L.; Sepúlveda-Viveros, Dino; Delgado, Edgard Narvaez; Lima, Elisangela da Costa; Chandia, Felipe Vera; Ferre, Felipe; Marin, Gustavo H.; Olmos, Ismael; Zimmermann, Ivan R.; Fulone, Izabela; Roldán-Saelzer, Juan; Sánchez-Salgado, Juan Carlos; Castro-Pastrana Lucila I.; Souza, Luiz Jupiter Carneiro de; Beltrán, Manuel Machado; Silva, Marcus Tolentino; Mena, María Belén; Fonteles, Marta Maria de; Urtasun, Martín A.; Tarapués, Monica; Hernández, Patricia Granja; Medero, Natalia; Herrera-Comoglio, Raquel; Barberato-Filho, Silvio; Galvão, Taís Freire; Luiza, Vera Lucia; Santa-Ana-Tellez, Yared; Rodríguez - Tanta, Yesenia; Elseviers, Monique
    Purpose: Drug utilization research (DUR) contributes to inform policymaking and to strengthen health systems. The availability of data sources is the first step for con- ducting DUR. However, documents that systematize these data sources in Latin American (LatAm) countries are not known. We compiled the potential data sources for DUR in the LatAm region. Methods: A network of DUR experts from nine LatAm countries was assembled and experts conducted: (i) a website search of the government, academic, and private health institutions; (ii) screening of eligible data sources, and (iii) liaising with national experts in pharmacoepidemiology (via an online survey). The data sources were char- acterized by accessibility, geographic granularity, setting, sector of the data, sources and type of the data. Descriptive analyses were performed. Results: We identified 125 data sources for DUR in nine LatAm countries. Thirty- eight (30%) of them were publicly and conveniently available; 89 (71%) were accessi- ble with limitations, and 18 (14%) were not accessible or lacked clear rules for data access. From the 125 data sources, 76 (61%) were from the public sector only; 46 (37%) were from pharmacy records; 43 (34%) came from ambulatory settings and; 85 (68%) gave access to individual patient-level data. Conclusions: Although multiple sources for DUR are available in LatAm countries, the accessibility is a major challenge. The procedures for accessing DUR data should be transparent, feasible, affordable, and protocol-driven. This inventory could permit a comparison of drug utilization between countries identifying potential medication- related problems that need further exploration.